Filing Overview
Pyxis Oncology, Inc. filed a Form 8-K under Item 5.07 reporting the results of its June 13, 2022 Annual Meeting of Stockholders. The meeting was conducted virtually. The filing does not provide operating or financial results for a reporting period.
Meeting and Voting Results
- As of the April 20, 2022 record date, 32,811,959 shares of common stock were outstanding and entitled to vote.
- Shares represented at the meeting totaled 20,554,982, establishing a quorum.
- Darren Cline was elected as a Class I director to serve until the 2025 Annual Meeting of Stockholders and until his successor is elected and qualified.
- Director election votes: 12,534,833 for, 44,547 withheld, and 7,975,603 broker non-votes.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Auditor ratification votes: 20,554,238 for, 720 against, 25 abstentions, and no broker non-votes.
Financial Metrics and Outlook
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating financial metrics. It also does not disclose material financial changes, contingencies, unusual items, or management outlook.
Important Facts to Verify
- Confirm the appointment and term of Darren Cline as a Class I director.
- Confirm Ernst & Young LLP’s ratification for the fiscal year ending December 31, 2022.
- Note the substantial broker non-votes in the director election, totaling 7,975,603 shares.
- The meeting occurred on June 13, 2022, while the filing was signed and dated June 14, 2022.